Taken together, the above data suggest that LSD1-regulated mechanisms may contribute to the resistance that, oftentimes, breast cancer cells develop against therapeutic agents, such as doxorubicin, commonly used in the oncological practice. The gene discussed is KDM1A; the disease is breast carcinoma.